Tevapharm

News & Media

Take a look inside our world

Press Releases



Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performanc...


Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Rev...


Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results De...


Teva Statement on European Commission Decision; Company to Appeal


Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab...


Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA


Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Cand...


Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide...


Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on Nove...


Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debili...
View all press releases

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com